Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), Allison Berger(Takeda (United States)), Michaël Thomas(Queen Alexandra Hospital), Sean A. Beausoleil(The University of Texas at San Antonio Health Science Center), Claudia M. Espitia(The University of Texas System), Michael A. Milhollen(Millennium Engineering and Integration (United States)), Anthony Possemato(Cell Signaling Technology (United States)), Kevin R. Kelly(Keck Hospital of USC), Peter G. Smith(Ollscoil na Gaillimhe – University of Galway), Stephen J. Blakemore(Epizyme (United States))
Cited by 117
Related Papers
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505